LTI-03 is being evaluated in the RENEW Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF). The company's LTI-01 has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusion. The pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.
Cyborg Score Rationale
Rein is advancing promising first-in-class therapies with recent Phase 2 initiation for its lead candidate, supported by analyst upgrades. However, the company trades at only $37M market cap with significant net losses, minimal revenue, and high volatility, reflecting typical early-stage biotech risk.
Top Insights
Lead candidate LTI-03 received orphan drug designation from EMA (January 2026) for IPF, a rare progressive lung disease
First patient dosed in Phase 2 RENEW trial represents major clinical milestone demonstrating proof-of-concept validation
Jones Trading initiated Buy coverage with undisclosed price target; Brookline Capital upgraded to Buy (January 2026)
Company operates with minimal revenue and negative earnings, typical for pre-commercial stage biotech requiring ongoing capital raises
Named Competitors
Ofev (nintedanib) — Standard-of-care tyrosine kinase inhibitor for IPF
Esbriet (pirfenidone) — Standard-of-care antifibrotic for IPF
Pirfenidone — Standard-of-care therapy for pulmonary fibrosis
Recent Developments
(January 2026) Received orphan drug designation from European Medicines Agency for LTI-03
(January 2026) Brookline Capital upgraded rating from Hold to Buy
(January 2026) Raised capital via private note offering to fund clinical development
(Early 2026) First patient dosed in RENEW Phase 2 trial of LTI-03
Open the full interactive Rein Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.